Different effects of biological drugs in rheumatoid arthritis

Autoimmunity Reviews

Volumn 12, Issue 5, 2013, Pages 575-579

  Atzeni, Fabiola ^a   Benucci, Maurizio ^b   Sallì, Salvatore ^c   Bongiovanni, Sara ^a   Boccassini, Laura ^a   Sarzi Puttini, Piercarlo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN GIOVANNI DI DIO HOSPITAL   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

Author keywords

Abatacept; Anti IL6; Anti TNF agents; Biological drugs; Rituximab

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIRHEUMATIC AGENT; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; METHOTREXATE; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB;

CLINICAL PRACTICE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; IMAGE ANALYSIS; INFECTION; MORPHOLOGY; OBSERVATIONAL STUDY; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ARTHRITIS, RHEUMATOID; CARTILAGE, ARTICULAR; CHONDROCYTES; DRUG THERAPY, COMBINATION; HUMANS; INFLAMMATION MEDIATORS; PHARMACEUTICAL PREPARATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875278357     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.10.020     Document Type: Review

References (40)

1. Lee D.M., Weinblatt M.E. Rheumatoid arthritis. Lancet 2001, 358:903-911.
2. Choy E.H.S., Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001, 344:907-916.
3. Feldmann M., Brennan F.M., Maini R.N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996, 14:397-440.
4. Atzeni F., Sarzi-Puttini P. Anti-cytokine antibodies for rheumatic diseases. Curr Opin Investig Drugs 2009, 10:1204-1211.
5. Atzeni F., Doria A., Maurizio T., Sarzi-Puttini P. What is the role of rituximab in the treatment of rheumatoid arthritis?. Autoimmun Rev 2007, 6:553-558.
6. Emery P. Early arthritis. Targeted therapies in rheumatology 2003, 509-513. Martin Dunitz, London. J.S. Smolen, P.E. Lipsky (Eds.).
7. Nell V.P., Machold K.P., Eberl G., Stamm T.A., Uffmann M., Smolen J.S. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004, 43:906-914.
8. Smolen J.S., Landewé R., Breedveld F.C., Dougados M., Emery P., Gaujoux-Viala C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
9. Olivieri I., Sarzi-Puttini P., Bugatti S., Atzeni F., d'Angelo S., Caporali R. Early treatment in early undifferentiated arthritis. Autoimmun Rev 2012, 11(8):589-592.
10. Caporali R., Pallavicini F.B., Filippini M., Gorla R., Marchesoni A., Favalli E.G., et al. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev 2009, 8:274-280.
11. Atzeni F., Sarzi-Puttini P., Gorla R., Marchesoni A., Caporali R. Switching rheumatoid arthritis treatments: an update. Autoimmun Rev 2011, 10:397-403.
12. Polachek A., Caspi D., Elkayam O. The perioperative use of biologic agents in patients with rheumatoid arthritis. Autoimmun Rev 2012, 12(2):164-168.
13. Wiens G.D., Glenney G.W. Origin and evolution of TNF and TNF receptor superfamilies. Dev Comp Immunol 2011, 35:1324-1335.
14. Agarwal S.K. Biologic agents in rheumatoid arthritis: an update for managed care professionals. J Manag Care Pharm 2011, 17:S14-S18.
15. Smolen J.S., Emery P. Infliximab: 12 years of experience. Arthritis Res Ther 2011, 13(Suppl. 1):S2.
16. Poddubnyy D., Rudwaleit M. Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Expert Opin Drug Saf 2011, 10:655-673.
17. Ash Z., Emery P. Golimumab - a new tool in the armamentaria against inflammatory arthritis. Ann Med 2011, 43:133-141.
18. Horton S., Walsh C., Emery P. Certolizumab pegol for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2012, 12:235-249.
19. Atzeni F., Sarzi-Puttini P. Twelve years' experience with etanercept in the treatment of rheumatoid arthritis: how it has changed clinical practice. Expert Rev Clin Immunol 2012, 8:213-222.
20. Keystone E.C., Curtis J.R., Fleischmann R.M., Furst D.E., Khanna D., Smolen J.S., et al. Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better long term outcomes: post-hoc analysis of a randomized controlled trial. J Rheumatol 2011, 38:990-996.
21. Curtis J.R., Luijtens K., Kavanaugh A. Predicting future response to certolizumab pegol in rheumatoid arthritis patients: Features at 12 weeks associated with low disease activity at 1 year. Arthritis Care Res (Hoboken) 2012, 64(5):658-667.
22. Nuki G., Bresnihan B., Bear M.B., McCabe D. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:2838-2846.
23. Fleischmann R.M., Schechtman J., Bennett R., Handel M.L., Burmester G.R., Tesser J., et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIl-1ra), in patients with rheumatoid arthritis. A large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003, 48:927-934.
24. Cohen S., Hurd E., Cush J., Schiff M., Weinblatt M.E., Moreland L.W., et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:614-624.
25. Leandro M.J., Becerra-Fernandez E. B-cell therapies in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2011, 25:535-548.
26. Tak P.P., Kalden J.R. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther 2011, 13(Suppl. 1):S5.
27. Finckh A., Ciurea A., Brulhart L., Möller B., Walker U.A., Courvoisier D., et al. Swiss Clinical Quality Management Programme for Rheumatoid Arthritis. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?. Ann Rheum Dis 2010, 69:387-393.
28. Brinkman I.H., van de Laar M.A., Jansen T.L., van Roon E.N. The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis. Expert Opin Drug Saf 2011, 10:715-726.
29. Solomon G.E. T-cell agents in the treatment of rheumatoid arthritis - 2011 update. Bull NYU Hosp Jt Dis 2011, 69:230-232.
30. Genovese M.C., Schiff M., Luggen M., Becker J.-C., Aranda R., Teng J., et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008, 67:547-554.
31. Genant H.K., Peterfy C.G., Westhovens R., Becker J.-C., Aranda R., Vratsanos G., et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 2008, 67:1084-1089.
32. Dayer J.M., Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology 2010, 49:15-24.
33. Jones G. The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis. Expert Rev Clin Immunol 2010, 6:189-195.
34. Emery P., Keystone E., Tony H., Cantagrel A., van Vollenhoven R., Sanchez A., et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial [RADIATE study]. Ann Rheum Dis 2008, 67:1516-1523.
35. Kremer J.L., Blanco R., Brzosko M., Burgos-Vargas R., Halland A.M., Vernon E., et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate at 1 year: the LITHE study. Arthritis Rheum 2011, 63:609-621.
36. Yazici Y., Curtis J.R., Ince A., Baraf H., Malamet R.L., Teng L.L., et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis 2012, 71:198-205.
37. Burmester G.R., Feist E., Kellner H., Braun J., Iking-Konert C., Rubbert-Roth A. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 2011, 70:755-759.
38. Salliot C., Finckh A., Katchamart W., Lu Y., Sun Y., Bombardier C., et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 2011, 70:266-271.
39. Scott D.L. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin Pharmacol Ther 2012, 91:30-43. [14].
40. Schoels M., Wong J., Scott D.L., Zink A., Richards P., Landewé R., et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010, 69:995-1003.